Group items tagged

More than 100 NHS clinicians have urged the National Institute for Health and Care Excellence (NICE) to change its decision - declining recommendation of romosozumab, the first new osteoporosis medication for over a decade. In a joint letter published on January 2, the clinicians warned of the consequences of barring access to the drug to those who suffer the bone-weakening disease. The joint letter, led by the Royal Osteoporosis Society (ROS), raised concern over the scarcity of the drug pipeline for osteoporosis and lack of public funding for new research. It quoted recent government research that showed the National Institute for Health Research (NIHR) invested less than £1 million in osteoporosis research in 2020-21, against the £4.6 billion per year cost to the NHS of fractures. Craig Jones, chief executive of the Royal Osteoporosis Society said: "We're calling on NICE and the applicant company to get back round the table and work with us to ensure equal access to this important new treatment.

The Omicron variant of coronavirus is less likely to cause long Covid than previous variants, according to the first peer-reviewed study of its kind from the UK. Researchers at King's College London, using data from nearly 100,000 people who logged their Covid symptoms via an app, found the odds of developing long Covid after infection were 20 per cent to 50 per cent lower during the Omicron wave in the UK compared to Delta. The figure varied depending on the patient's age and the timing of their last vaccination. Long Covid, which includes prolonged symptoms ranging from fatigue to 'brain fog', can be debilitating and continue for weeks or months. It is increasingly being recognised as a public health problem, and researchers have been racing to find out if Omicron presents as big a risk of long Covid as previously dominant variants. The study from King's is believed to be the first academic research to show Omicron does not present as great a risk of long Covid, but that does not mean long Covid patient numbers are dropping, the team said. While the risk of long Covid was lower during Omicron, more people were infected, so the absolute number now suffering is higher. "It's good news, but please don't decommission any of your long Covid services," lead researcher Dr Claire Steves said, appealing to health-service providers.

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

Early detection and treatment of Alzheimer's disease require the use of dependable and cost-effective screening technologies. Researchers at Sweden's Karolinska Institutet have revealed that the level of tau, a protein that plays a vital role in the development of severe dementia, is associated with a kind of sugar molecule in the blood. The study, which is published in Alzheimer's & Dementia, can pave the way for a simple screening procedure able to predict onset ten years in advance. "The role of glycans, structures made up of sugar molecules, is a relatively unexplored field in dementia research," says the study's first author Robin Zhou, medical student and affiliated researcher at the Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet. "We demonstrate in our study that blood levels of glycans are altered early during the development of the disease. This could mean that we'll be able to predict the risk of Alzheimer's disease with only a blood test and a memory test." In Alzheimer's disease, the neurons of the brain die, which is thought to be a result of the abnormal accumulation of the proteins amyloid beta and tau. Clinical trials for Alzheimer's drugs show that treatment should commence early in the pathological process, before too many neurons have died, to reverse the process before it is too late.

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre. The donation - the biggest in the university's history - will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide. The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding. He and Sam were on Thursday (April 20) joined by specially invited guests from across the region's health, education, and business communities, to launch the Institute housed in the University's Sciences Complex. Unveiling a plaque inside the building, John said: "It's an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today. "It's been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago. "I was immediately impressed at what has been achieved in that intervening half-century and I've been delighted to assist the University continue its development, particularly in the health arena. "I hope the launch of this institute will mark the next phase in the University's evolution and I'm very much looking forward to working with the team as they bring their projects to fruition."

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have been tasked to evaluate the impact, safety and effectiveness of the Pharmacy First service, which was launched across England in January 2024. They have been awarded £2.4million by the National Institute for Health and Care Research (NIHR) to generate evidence on the new service that allows pharmacies to provide advice and treatment for seven common conditions without the need for a GP appointment. After consultation, if necessary, a community pharmacist can supply some prescription-only medicines to treat earache, sore throat, sinusitis, impetigo, shingles, infected insect bites or uncomplicated urinary tract infections in women. The LSHTM researcher team will be working together with experts at the UK Health Security Agency (UKHSA) and the Universities of Oxford, Manchester and Nottingham on the project. Dr Rebecca Glover, assistant professor in Antimicrobial Resistance at LSHTM, who will lead the three-year project, said they will evaluate "Pharmacy First's impact on GPs and the wider NHS, pharmacy services and patients."

Researchers from King's College London and the University of Helsinki have identified a link between periodontitis (gum disease) and cryptogenic ischemic stroke, which causes a blockage in the blood vessel supplying blood to a region of the brain. The findings, recently published in the Journal of Dental Research, emphasise severe gum disease as a risk factor for young-onset stroke, particularly in patients with no other identifiable risk factors. Dr. Susanna Paju, Periodontology Specialist from the University of Helsinki, led the study in collaboration with Dr. Svetislav Zaric, Clinical Lecturer in Periodontology from King's College London. Dr. Zaric explains the implications of their research: "Stroke remains the second leading cause of death globally. Strikingly, the incidence and prevalence of ischemic stroke have been increasing in the younger population during past decades," she said. "Periodontitis, which involves deep inflammation of the gums due to bacteria under the gumline, can lead to systemic effects as bacteria enter the bloodstream and affect other parts of the body," she added.

Cancer Research UK has announced a £56m research network to transform the UK into a global hub for radiotherapy study. By leveraging the use of the latest techniques, such as FLASH radiotherapy and artificial intelligence (AI), the network aims to accelerate the development of advanced radiotherapy.

Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

The materials cover various health topics and are developed through patient-centered outcomes research. The site also provides materials for researchers and others interested in the systematic study of evidence and research methods.

While this study offers a slice of hope for victims, the further research is required. According to researchers, because of the potential treatments' anti-tumoral results, advances in therapy treatment may be further explored.

Cerebral palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child. These lead to damage or delayed development in the brain. The disorder is permanent and, though it does not worsen with age, the level of functionality of a person with cerebral palsy varies widely: in some cases, effects may be very minor, while in others, movement is impaired to the extent that a wheelchair is required. Common complications associated with CP vary by the type of CP disorder but can include vision problems, seizures, learning disabilities, and issues speaking, writing, and performing other tasks related to motor control. Cerebral palsy is the focus of a large amount of medical research every year. Though much of this research deals with younger patients, more and more attention is being paid to CP sufferers as they age and seek fuller opportunities and more integration with the rest of society. Living with CP is a daily challenge, but paths to a richer and more fulfilling life are being found. There is not, and may never be a "cure" for CP, but greater understanding by clinicians and the daily success stories of those who overcome their limitations are making. Buy online CP Wheelchair, Pediatric Cerebral Palsy Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair for handicapped and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Karma CP Wheelchair, Pediatric Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair at low price in india. Causes of Cerebral Palsy Cerebral palsy is generally caused by developmental issues during pregnancy which lead to abnormal conditions in the brain. During the birth process, lack of oxygen caused by premature delivery or delivery-room errors can cause brain damage that facilitates cerebral palsy. Cerebral palsy can also be caused by recognizable brain injuries sustained by the developing child up to an early

The study estimates the Vascular Graft market size for 2018 and projects its demand till 2023. In the primary research process, various sources from both demand side and supply side were interviewed to obtain qualitative and quantitative information for the report. Primary sources from the demand side include research scientists, Vascular Graft specialists, laboratory technicians, and R&D professionals of pharmaceutical and biotechnology companies and academic research institutes.

Researchers have projected the rates of liver disease and associated deaths due to increased alcohol consumption during the Covid-19 pandemic. The research has been published in the 'Hepatology Journal'. A team led by investigators at Massachusetts General Hospital used data from a national survey of US adults on their drinking habits that found that excessive drinking (such as binge drinking) increased by 21 per cent during the Covid-19 pandemic. The scientists simulated the drinking trajectories and liver disease trends in all US adults. They estimated that a one-year increase in alcohol consumption during the Covid-19 pandemic will result in 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040. In the short term, alcohol consumption changes due to Covid-19 are expected to cause 100 additional deaths and 2,800 additional cases of liver failure by 2023. The researchers noted that a sustained increase in alcohol consumption for more than one year could result in 19-35 per cent additional mortality.

Baby teeth could one day lead to the development of a much-needed tool for identifying children who are at risk for psychological problems, a study by the University of Bristol has concluded. The research has been published in the 'JAMA Network Open' - a monthly journal published by the American Medical Association. The origin of this study traces back several years, when senior author Erin Dunn - a social and psychiatric epidemiologist and an investigator in MGH's Psychiatric and Neurodevelopmental Genetics Unit - learned about work in the field of anthropology that could help solve a longstanding problem in her own research. She studies the effects of childhood adversity, which research suggested, is responsible for up to one-third of all mental health disorders. Dunn is particularly interested in the timing of these adverse events and in uncovering whether there are sensitive periods during child development when exposure to adversity is particularly harmful.

Researchers from the University of Oxford today (December 8) started recruiting for a clinical trial to test novel antiviral Covid-19 treatments for early use in the illness by people in the community and those who are at higher risk of complications. Partnering with the National Institute for Health Research (NIHR), colleagues in several UK universities, and the NHS UK-wide, the Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC), is a national priority trial, and will be open to participants from across the UK. The first treatment to be tested by the UK Antiviral Taskforce will be molnupiravir, a Covid antiviral pill already licensed by the MHRA. Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.

The Medicines and Healthcare products Regulatory (MHRA) and Genomics England to launch a brand-new genetic research resource, known as a 'biobank' on Thursday (June 01) to tackle the issue of Adverse Drug Reactions (ADRs). Biobank will help to better understand how a patient's genetic makeup can impact the safety of their medicines. "The Yellow Card biobank, which will contain genetic data and patient samples, will operate alongside the MHRA's Yellow Card reporting site for suspected side effects and adverse incidents involving medicines and medical devices," said MHRA. The biobank pilot will officially begin on 1 June 2023 with participant recruitment commencing later this year, on 1 September. The sequencing of participants' genetic material will begin in Spring 2024, with initial research findings from the pilot due to be published in 2025. Genomics England will be supporting the MHRA with sequencing and storage of genetic material through use of their well-established and secure infrastructure.

New research has shown that chronic pain can be objectively measured using brain signals, a report in The Conversation said. According to the report, a team of researchers conducted a study using brain implants capable of recording neural signals over an extended period. Their aim was to identify reliable markers of chronic pain severity in four patients as they went about their daily lives. While pain is typically a subjective experience, there is still much to discover about how pain signals are processed in the brain. Previous studies often relied on artificial settings, and the relationship between acute and chronic pain circuits remained unclear. To investigate this further, the researchers surgically implanted electrodes in the brains of four patients experiencing post-stroke pain and phantom limb pain. Neural signals were recorded in specific brain regions associated with planning, expectation, and emotion. The patients were then asked to report their pain severity levels multiple times a day for up to six months. Machine learning models were developed to analyse the recorded brain activity signals and predict the patients' self-reported pain intensity scores.